Success Metrics

Clinical Success Rate
25.0%

Based on 1 completed trials

Completion Rate
25%(1/4)
Active Trials
18(49%)
Results Posted
0%(0 trials)
Terminated
3(8%)

Phase Distribution

Ph phase_3
15
41%
Ph phase_1
6
16%
Ph phase_2
13
35%
Ph not_applicable
1
3%
Ph phase_4
2
5%

Phase Distribution

6

Early Stage

13

Mid Stage

17

Late Stage

Phase Distribution37 total trials
Phase 1Safety & dosage
6(16.2%)
Phase 2Efficacy & side effects
13(35.1%)
Phase 3Large-scale testing
15(40.5%)
Phase 4Post-market surveillance
2(5.4%)
N/ANon-phased studies
1(2.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

20.0%

1 of 5 finished

Non-Completion Rate

80.0%

4 ended early

Currently Active

18

trials recruiting

Total Trials

37

all time

Status Distribution
Active(20)
Completed(1)
Terminated(4)
Other(12)

Detailed Status

Recruiting14
unknown12
Active, not recruiting4
Terminated3
Completed1
Enrolling by invitation1

Development Timeline

Analytics

Development Status

Total Trials
37
Active
18
Success Rate
25.0%
Most Advanced
Phase 4

Trials by Phase

Phase 16 (16.2%)
Phase 213 (35.1%)
Phase 315 (40.5%)
Phase 42 (5.4%)
N/A1 (2.7%)

Trials by Status

completed13%
recruiting1438%
enrolling_by_invitation13%
withdrawn13%
active_not_recruiting411%
not_yet_recruiting13%
terminated38%
unknown1232%

Recent Activity

Clinical Trials (37)

Showing 20 of 37 trialsScroll for more
NCT06474455Phase 1

A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors

Recruiting
NCT06828354Phase 3

A Study of SHR-A1811 in Subjects With Ovarian Cancer

Recruiting
NCT07168200Phase 3

A Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the Treatment of Locally Advanced Cervical Cancer

Recruiting
NCT03315364Phase 2

Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy

Active Not Recruiting
NCT04379635Phase 3

Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)

Active Not Recruiting
NCT07331155Phase 2

A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]

Recruiting
NCT07042802Phase 1

A Phase Ib/Ⅱ Clinical Trial of LBL-024 Combined With Paclitaxel in Patients With Platinum-resistant Ovarian Cancer

Recruiting
NCT06783647Phase 2

A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]

Recruiting
NCT07360132Phase 3

Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer

Not Yet Recruiting
NCT06513364Phase 1

Neoadjuvant Chemotherapy With WH002 in Women With HER2-negative Breast Cancer

Completed
NCT05481645Phase 2

Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.

Terminated
NCT06078384Phase 2

Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC

Recruiting
NCT05326035Phase 1

A Study of WJ05129 in Advanced Malignant Solid Tumors

Terminated
NCT06840002Phase 1

A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer

Recruiting
NCT04158362Phase 3

Endocrine Therapy With Abemaciclib or Chemotherapy as Initial Metastatic Treatment in ER+/HER2- Breast Cancer

Active Not Recruiting
NCT04778839Phase 1

Study of Paclitaxel Micelles for Injection in Chinese Patients With Advanced Solid Tumors.

Recruiting
NCT06738251Phase 3

A Phase III Study of SHR-A2102 Versus Investigator-selected Therapy in Advanced Urothelial Carcinoma

Recruiting
NCT06237257Phase 2

A Study of Chemoradiotherapy With SHR-1316 For Treatment of Locally Advanced Cervical Cancer

Active Not Recruiting
NCT06378177Phase 2

A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC)

Recruiting
NCT06221748Phase 2

DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy

Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
37